{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:28:11Z","timestamp":1793399291282,"version":"4.5.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Small-interfering RNA (siRNA) targeting hepatic AGT (angiotensinogen) mRNA depletes AGT, lowering blood pressure for up to 6 months. However, certain situations may require a rapid angiotensin increase. The REVERSIR (RVR) - reverse siRNA silencing technology a potential approach to counteract siRNA effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Spontaneously hypertensive rats received 10 mg\/kg AGT siRNA, and 3 weeks later were given AGT-RVR (1, 10, or 20 mg\/kg). One week after AGT-RVR dosing, a redose of AGT siRNA assessed its post-AGT-RVR effectiveness for 2 weeks. Additionally, the impact of AGT-RVR after an equihypotensive dose of valsartan (4 mg\/kg per day) was examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Baseline mean arterial pressure (MAP) was 144\u00b11 mm\u2005Hg. AGT siRNA reduced MAP by \u224816 mm\u2005Hg and AGT by &gt;95%, while renin increased 25-fold. All AGT-RVR doses restored MAP to baseline within 4 to 7 days. Notably, 10 and 20 mg\/kg restored AGT and renin to baseline, while 1 mg\/kg allowed \u224850% AGT restoration, with renin remaining above baseline. A second AGT siRNA treatment, following 1 mg\/kg AGT-RVR, reduced MAP to the same degree as the initial dose, while following 10 mg\/kg AGT-RVR, it resulted in \u224850% of the first dose\u2019s MAP effect at 2 weeks. The valsartan-induced MAP reduction was unaffected by AGT-RVR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>In spontaneously hypertensive rats, angiotensinogen-RVR dose-dependently reversed AGT siRNA-induced AGT reduction, normalizing MAP. MAP normalization persisted even with 50% recovered AGT levels, likely due to upregulated renin maintaining adequate angiotensin generation. Post-AGT-RVR dosing, a second AGT siRNA dose lowered MAP again.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/hypertensionaha.124.22878","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T05:00:26Z","timestamp":1714539626000},"page":"1491-1499","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Counteracting Angiotensinogen Small-Interfering RNA-Mediated Antihypertensive Effects With REVERSIR"],"prefix":"10.1161","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6433-5032","authenticated-orcid":true,"given":"Dien","family":"Ye","sequence":"first","affiliation":[{"name":"Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, the Netherlands (D.Y., E.O.C.-L., R.v.V., I.M.G., A.H.J.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4810-5720","authenticated-orcid":true,"given":"Edwyn O.","family":"Cruz-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, the Netherlands (D.Y., E.O.C.-L., R.v.V., I.M.G., A.H.J.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2249-1002","authenticated-orcid":true,"given":"Richard van","family":"Veghel","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, the Netherlands (D.Y., E.O.C.-L., R.v.V., I.M.G., A.H.J.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2061-6737","authenticated-orcid":true,"given":"Ingrid M.","family":"Garrelds","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, the Netherlands (D.Y., E.O.C.-L., R.v.V., I.M.G., A.H.J.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Kasper","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA (A.K., K.W., H.-C.T., I.Z.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Wassarman","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA (A.K., K.W., H.-C.T., I.Z.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8904-8239","authenticated-orcid":true,"given":"Ho-Chou","family":"Tu","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA (A.K., K.W., H.-C.T., I.Z.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2797-3032","authenticated-orcid":true,"given":"Ivan","family":"Zlatev","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA (A.K., K.W., H.-C.T., I.Z.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H. Jan","family":"Danser","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, the Netherlands (D.Y., E.O.C.-L., R.v.V., I.M.G., A.H.J.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.02893"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.18731"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208391"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.12703"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja505986a"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz140"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.12.021"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0736"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa077"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.16876"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15955"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20201239"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026426"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4136"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.29.6.1240"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp012"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.96.1.220"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.124.22878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T17:43:47Z","timestamp":1756835027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.124.22878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.124.22878"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.124.22878","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-02-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}